Published in Clin Exp Med on June 17, 2011
Bone marrow angiogenesis in multiple myeloma. Leukemia (2006) 1.47
Angiogenesis in pre-malignant conditions. Eur J Cancer (2009) 1.45
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol (2007) 1.29
The role of the vascular phase in solid tumor growth: a historical review. Neoplasia (1999) 1.20
Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer (2005) 1.02
Morphological and molecular aspects of physiological vascular morphogenesis. Angiogenesis (2009) 1.02
Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res (2004) 0.98
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist (2009) 0.97
Microvessel density in unknown primary tumors. Int J Cancer (1997) 0.92
Matrix metalloproteinases in carcinoma of unknown primary. Cancer (2005) 0.87
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
Sonographic quantitative evaluation of scrotal veins in healthy subjects: normative values and implications for the diagnosis of varicocele. Eur Urol (2006) 2.17
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J (2007) 2.11
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica (2003) 1.97
Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res (2007) 1.79
The gelatin sponge-chorioallantoic membrane assay. Nat Protoc (2006) 1.77
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res (2006) 1.72
Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica (2002) 1.69
Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. Am J Obstet Gynecol (2005) 1.69
Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J (2002) 1.61
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem (2006) 1.59
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. Leuk Res (2007) 1.48
The role of podoplanin in tumor progression and metastasis. Anticancer Res (2008) 1.48
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica (2002) 1.47
Angiogenesis in pre-malignant conditions. Eur J Cancer (2009) 1.45
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res (2003) 1.45
Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res (2004) 1.41
The adaptor protein p66Shc is a positive regulator in the angiogenic response induced by hypoxic T cells. J Leukoc Biol (2009) 1.40
A portrait of Aristotle as an anatomist: historical article. Clin Anat (2007) 1.40
Mondino de' Liuzzi and his Anothomia: a milestone in the development of modern anatomy. Clin Anat (2006) 1.38
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res (2006) 1.37
Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J (2002) 1.37
Endothelial cell heterogeneity and organ specificity. J Hematother Stem Cell Res (2002) 1.35
A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc Res (2004) 1.35
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst (2006) 1.32
Nerve growth factor as an angiogenic factor. Microvasc Res (2007) 1.32
MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst (2013) 1.31
Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol (2008) 1.30
Analysis of the role of chemokines in angiogenesis. J Immunol Methods (2003) 1.30
Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene. Mol Pharmacol (2005) 1.27
Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev (2011) 1.24
Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J Anat (2004) 1.22
The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol (2008) 1.21
Severe alterations of endothelial and glial cells in the blood-brain barrier of dystrophic mdx mice. Glia (2003) 1.21
Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res (2002) 1.16
Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res (2009) 1.16
Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets (2011) 1.15
Endothelial cells in the bone marrow of patients with multiple myeloma. Blood (2003) 1.15
HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A (2012) 1.15
Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res (2008) 1.14
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res (2011) 1.12
Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol (2005) 1.11
Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev (2006) 1.10
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res (2010) 1.09
Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol (2010) 1.09
Piecemeal degranulation as a general secretory mechanism? Anat Rec A Discov Mol Cell Evol Biol (2003) 1.09
The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms. Clin Biochem (2011) 1.08
In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J (2001) 1.06
Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol (2011) 1.06
Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol (2005) 1.05
Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res (2007) 1.05
Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin Cancer Res (2012) 1.05
Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol (2009) 1.05
Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. Br J Haematol (2003) 1.04
Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol (2005) 1.04
Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. Cancer Lett (2008) 1.04
Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J Allergy Clin Immunol (2009) 1.04
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood (2006) 1.04
Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A (2007) 1.03
Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol (2005) 1.03
The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine Growth Factor Rev (2007) 1.02
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica (2011) 1.02
The role of adrenomedullin in angiogenesis. Peptides (2005) 1.02
Angiogenesis in neuroblastoma. Ann N Y Acad Sci (2004) 1.02
Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clin Exp Med (2013) 1.01
Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol (2003) 1.00
Morphofunctional aspects of the blood-brain barrier. Curr Drug Metab (2012) 1.00
Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol (2005) 1.00
Long-term changes to in vitro preserved bioengineered human trachea and their implications for decellularized tissues. Biomaterials (2012) 1.00
Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem (2004) 0.99
The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep (2010) 0.99
Neovascularization and mast cells with tryptase activity increase simultaneously in human pterygium. J Cell Mol Med (2007) 0.99
Endothelial progenitor cells in sudden sensorineural hearing loss. Acta Otolaryngol (2010) 0.98
Novel strategies in the treatment of castration-resistant prostate cancer (Review). Int J Oncol (2012) 0.98
The role of microenvironment in tumor angiogenesis. Genes Nutr (2008) 0.98
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res (2003) 0.98
Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia (2009) 0.98
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther (2005) 0.98
Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev (2008) 0.98
Soluble intercellular adhesion molecule 1 and soluble vascular cell adhesion molecule 1 in sudden hearing loss. Otol Neurotol (2008) 0.97
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res (2008) 0.97
Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma. Peptides (2008) 0.97
Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice. Pharmacol Res (2011) 0.96
Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematol J (2004) 0.96
Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2. Peptides (2008) 0.96